59 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
Therapeutics, Inc merger agreement and severance and other related costs for former TCR2 Therapeutics leadership, offset by a decrease in share-based
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
products, and the company culture. Cintia was instrumental in designing and steering our commercial model design and her leadership will be critical … and Gene Strategy & Program Management Office, for Kymriah and the CAR-T pipeline, leading the cross-functional leadership teams for business (marketing
8-K
EX-99.1
2u3l56c97q03mz
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
6pqsy
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.3
hw2ijjj7
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
iz2k36m6vf4d h3mzd
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
u7zswf
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
vu8jer6fkok2inex3r7
22 May 23
Business combination disclosure
7:01am
8-K
6ckwiri
22 May 23
Other Events
6:59am
424B3
pwy4wf
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
jyqi1acipl wxwtrqwn
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-99.1
043qlwok
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-10.1
mgja39 f8
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
8mnr9bwrk18qpjwk7nc1
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm